Publications
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat.…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity…
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological…
Insights
Around the World in HTA: Japan – An algorithmic approach to containing costs
14 April 2026
Japan’s health technology assessment (HTA) system uses algorithmic drug…
Seven reflections on the UK EQ-5D-5L value set – and what comes next
30 March 2026
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment…
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined…
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5…
Around the World in HTA: Japan – An algorithmic approach to containing costs
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage…
Drug Development/R&D
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5…
Europe’s pharmaceutical policy choices – And what the United States stands to learn
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw…
Digital Health
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and…
OHE’s submission for the DHSC’s next 10 years of planning
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation…
Prevention
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible…
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at the NHS 10 Year Health Plan, concluding that…
Events
OHE events sharing innovation and insights
Masterclass: Cost-effectiveness thresholds in health technology assessment
28 April 2026, 1:00pm
Join us for an in‑depth Masterclass that unpacks one of the most influential—and often misunderstood—elements of…
